Enhanced bone augmentation by controlled release of recombinant human bone morphogenetic protein-2 from bioabsorbable membranes.
BACKGROUND
The present study was undertaken to determine the effect of recombinant human bone morphogenetic protein-2 (rhBMP-2)-loaded biodegradable membranes on bone augmentation in a rabbit calvarial model.


METHODS
Five microg of rhBMP-2 was loaded into a stiff hemispherical dome membrane made of poly(L-lactide) and tricalcium phosphate (PLLA/TCP). The release kinetics of rhBMP-2 from the membrane were determined in vitro using a human BMP-2 immunoassay. Twelve rhBMP-2-loaded dome membranes (test group) and 12 control dome membranes (control group) were placed on the partial-thickness calvarial defects of 24 rabbits. The animals were sacrificed at 4 and 8 weeks, and undecalcified ground sections were prepared. Newly formed bone area and height were measured histomorphometrically and calculated by percentage ratio to the total submembranous space area and height below the dome.


RESULTS
In vitro release results demonstrated that rhBMP-2 was released consistently over a 4-week period following a high initial burst release on the first day. At both 4 and 8 weeks, histomorphometric analysis revealed that the test group showed significantly higher newly formed bone heights and areas than the control group (P < 0.01). In the control group, new bone height was 36.3% of the dome height and the new bone area reached 8.2% of the submembranous space area at 8 weeks, while the test group reached 87.3% and 35.4%, respectively.


CONCLUSIONS
These results suggest that the use of rhBMP-2-loaded PLLA/TCP membranes can result in additional bone augmentation, which is due to the osteoinductive properties of rhBMP-2 released from the membrane during healing.
Lee
Yong-Moo
YM
Department of Periodontology and Brain Korea 21 Human Life Science, College of Dentistry, Seoul National University, Seoul, Korea. ymlee@snu.ac.kr
Nam
Sung-Heon
SH
Seol
Yang-Jo
YJ
Kim
Tae-Il
TI
Lee
Seung-Jin
SJ
Ku
Young
Y
Rhyu
In-Chul
IC
Chung
Chong-Pyoung
CP
Han
Soo-Boo
SB
Choi
Sang-Mook
SM
D020341:Absorbable Implants; D000818:Animals; D001672:Biocompatible Materials / Q000737:chemistry; D001847:Bone Diseases / Q000473:pathology / Q000601:surgery*; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000008:administration & dosage*; D002130:Calcium Phosphates / Q000737:chemistry; D003692:Delayed-Action Preparations; D004195:Disease Models, Animal; D016503:Drug Delivery Systems; D006801:Humans; D008567:Membranes, Artificial; D010012:Osteogenesis / Q000187:drug effects; D011091:Polyesters / Q000737:chemistry; D011817:Rabbits; D011897:Random Allocation; D011994:Recombinant Proteins; D012886:Skull / Q000473:pathology / Q000601:surgery*; D016212:Transforming Growth Factor beta / Q000008:administration & dosage*; D014945:Wound Healing / Q000187:drug effects
C525718:BMP2 protein, human; D001672:Biocompatible Materials; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D002130:Calcium Phosphates; D003692:Delayed-Action Preparations; D008567:Membranes, Artificial; D011091:Polyesters; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C485817:beta-tricalcium phosphate; C499469:recombinant human bone morphogenetic protein-2; C033616:poly(lactide); C018392:tricalcium phosphate